Common Stock
- Symbol
- ICCC
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
ImmuCell Corporation
ICCCNASDAQEQUITYCurrent
Results of Operations and Financial Condition
ITEM 2.02. Results of Operations and Financial Condition On October 12, 2026 ImmuCell Corporation (the "Company") issued a press release announcing a 46% increase in product sales in quarter three of 2026 as compared to quarter three of 2025, based on preliminary, unaudited sales results for the quarter ended September 30, 2026.…
Company context
ImmuCell Corporation’s (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, which provides Immediate Immunity™ to newborn dairy and beef calves, and is developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without FDA-required milk discard or pre-slaughter withdrawal label restrictions that provides an alternative to traditional mastitis antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com.
Current securities
Registered securities in this filing
ImmuCell Corporation · 8-K · Filed 2026-10-13
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
ITEM 2.02. Results of Operations and Financial Condition
On October 12, 2026 ImmuCell Corporation (the "Company") issued a press release announcing a 46% increase in product sales in quarter three of 2026 as compared to quarter three of 2025, based on preliminary, unaudited sales results for the quarter ended September 30, 2026. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.